Recent News

• 06.12.2025 - Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
• 06.12.2025 - Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
• 06.12.2025 - Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
• 06.12.2025 - Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.05.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 06.05.2025 - Jefferies Global Healthcare Conference
• 05.29.2025 - Syndax Announces Participation in June Investor Conferences
• 05.29.2025 - Syndax Announces Participation in June Investor Conferences
• 05.28.2025 - TD Cowen 6th Annual Oncology Innovation Summit

Recent Filings

• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 3 Initial statement of beneficial ownership of securities
• 05.16.2025 - 8-K Current report
• 05.16.2025 - EX-99.1 EX-99.1